Valneva SE announced the earnings guidance for 2024. For the year Product sales expected between ?150 million and ?180 million, reflecting continued revenue growth for proprietary products and IXCHIQ®?s launch-year sales, despite anticipated supply constraints for third-party products and IXIARO®.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
3.968 EUR | -1.05% | -2.17% | -15.93% |
May. 21 | Valneva Names New Chief Scientific Officer | MT |
May. 21 | Valneva appoints Scientific Director | CF |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-15.93% | 605M | |
+64.92% | 62.59B | |
-1.85% | 41.18B | |
+44.76% | 40.29B | |
-8.93% | 27.9B | |
+13.05% | 26.21B | |
-21.96% | 19.09B | |
+4.21% | 13.08B | |
+25.74% | 12.26B | |
+27.42% | 12.05B |
- Stock Market
- Equities
- VLA Stock
- News Valneva
- Valneva Se Announces Earnings Guidance for 2024